Author Interviews, Cost of Health Care, HIV, Lancet / 13.11.2017
HIV PreExposure Prophylaxis -PrEP- For MSM Found To Be Effective and Cost Saving
MedicalResearch.com Interview with:
[caption id="attachment_38292" align="alignleft" width="97"]
Dr. Cambiano[/caption]
Dr Valentina Cambiano PhD
Institute for Global Health
University College London
London UK
MedicalResearch.com: What is the background for this study?
Response: Pre-Exposure Prophylaxis (PrEP) which involves the use of drugs, which are used to treat HIV, in people without HIV to prevent them from getting is a critical new advance in HIV prevention. It has been shown to reduce the risk of HIV infection by 86% and the benefits heavily out-weigh any concerns. However, introducing this intervention has a cost.
When we started working on this study the National Health Services was discussing whether to introduce PrEP and if so for which populations. Unfortunately, at the moment NHS England is not providing Pre-exposure prophylaxis. However, a large study, the PrEP impact trial, funded by the NHS, has just started and this will provide PrEP to 10,000 people.
Dr. Cambiano[/caption]
Dr Valentina Cambiano PhD
Institute for Global Health
University College London
London UK
MedicalResearch.com: What is the background for this study?
Response: Pre-Exposure Prophylaxis (PrEP) which involves the use of drugs, which are used to treat HIV, in people without HIV to prevent them from getting is a critical new advance in HIV prevention. It has been shown to reduce the risk of HIV infection by 86% and the benefits heavily out-weigh any concerns. However, introducing this intervention has a cost.
When we started working on this study the National Health Services was discussing whether to introduce PrEP and if so for which populations. Unfortunately, at the moment NHS England is not providing Pre-exposure prophylaxis. However, a large study, the PrEP impact trial, funded by the NHS, has just started and this will provide PrEP to 10,000 people.






















